Indraneel Sanyal

Senior Director @Aragen Life Sciences

Bengaluru, KA, IN
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Dec 2023 — Present

Senior Director @Aragen Life Sciences

View department →

Bengaluru, IN

EDUCATION

1988 — 1991

MS university of baroda

B.Sc, Zoology

1991 — 1993

MS university of Baroda

M.Sc, Microbiology

SKILLS

Protein ChemistryRegulatory CommunicationsQuality by DesignPre-Clinical StudiesScale UpLifesciencesPurificationTechnology TransferAnalytical UltracentrifugationMolecular BiologyProcess SimulationClinical TrialsDownstream ProcessingMonoclonal AntibodiesValidationVaccineBiotechnologyProtein PurificationGmpFermentation Process DevelopmentPharmacodynamicsBiopharmaceuticalsCell CultureRegulatory DocumentationImmunogenicityChromatography

ABOUT INDRANEEL SANYAL

Biotech professional with more than 3 decades of experience in developing robust commercial-scale Biotherapeutic processes and Technology transfer.Have led the Biologics business unit of Eurofins Advinus and Process Development group of Biologics at Syngene International Limited. Proficient in building customized technical roadmaps from Gene to the clinic for novel Biotherapeutics, Process development of Advanced therapeutics medicinal products, Early phase accelerated development roadmaps, risk assessment, and mitigation strategies. Core expertise in the area of Clinical phase-specific project execution (Project planning, Resource mapping & management) Process Development and Characterization, Technology evaluation, and transfer. Portfolio of molecules developed and supplied for clinical and commercial use: rHu Vaccines for infectious & non-infectious diseases, progressing from development to WHO supply. Therapeutic & CAR-T monoclonal antibodies (both full length & engineered), developed for regulated market Clinical supply. Cytokines, advancing from Proof of Concept to Late-stage Clinical supply. Hormones, taken through the process of development to Technology out-licensing. Growth factors, moving from Proof of Concept to Early phase Clinical supply. Recombinant Thrombolytic agents, developed and supplied for IND-Tox studies. Subcutaneous High concentration monoclonal antibody formulations, in the stages of development.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Indraneel Sanyal — Senior Director at Aragen Life Sciences in Bengaluru, KA, IN | Unifers